Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate ...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Alector Inc. (ALEC) on Wednesday reported a loss of $2.1 million in its fourth quarter. The South San Francisco, California-based ...

SOUTH SAN FRANCISCO - Alector, Inc. (NASDAQ: ALEC) reported fourth quarter 2024 results that significantly exceeded analyst expectations, sending shares up 1.7% in after-hours trading.

Guidance. Management anticipates, for the year ending 2025, collaboration revenue to be between $5M and $15M , total research and ...

Cash, cash equivalents, and investments were $413.4 M as of December 31. Management expects that this will be sufficient to fund ...

Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Alector (NASDAQ:ALEC – Get Free Report) is anticipated to post its quarterly earnings results after the market closes on ...

Alector (NASDAQ:ALEC) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close. The consensus EPS Estimate is -$0.54 (-10.2% Y/Y) and the consensus Revenue Estimate ...

Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...